St. Jude Gearing For SCD-HeFT Implants, Anticipates Medicare Rewards
This article was originally published in The Gray Sheet
Executive SummarySt. Jude Medical will start to reap the benefits of Medicare's coverage policy for implantable cardioverter defibrillators now that CMS has established an ICD registry, the company predicted April 21 during its first-quarter earnings call
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.